Palbociclib resistance confers dependence on an FGFR-MAP kinase-mTOR-driven pathway in KRAS-mutant non-small cell lung cancer

CDK4 is emerging as a target in KRAS-mutant non-small cell lung cancer (NSCLC). We demonstrate that KRAS-mutant NSCLC cell lines are initially sensitive to the CDK4/6 inhibitor palbociclib, but readily acquire resistance associated with increased expression of CDK6, D-type cyclins and cyclin E. Resi...

Descripción completa

Detalles Bibliográficos
Autores principales: Haines, Eric, Chen, Ting, Kommajosyula, Naveen, Chen, Zhao, Herter-Sprie, Grit S., Cornell, Liam, Wong, Kwok-Kin, Shapiro, Geoffrey I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Priority Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114982/
https://www.ncbi.nlm.nih.gov/pubmed/30167080
http://dx.doi.org/10.18632/oncotarget.25803

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6114982/
https://www.ncbi.nlm.nih.gov/pubmed/30167080
http://dx.doi.org/10.18632/oncotarget.25803

Ejemplares similares